arrow
R

Régis Peffault de Latour

hôpital saint-louis
H指数:73
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term NSAID efficacy in haematological and bone manifestation of Ghosal haematodiaphyseal dysplasia: An expanded cohort

格萨尔血骨发育异常的血液学及骨骼表现中NSAID的长期疗效:一项扩展队列研究

2026-10-210
OA
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study

eltrombopag添加到标准免疫抑制治疗中作为一线疗法治疗重症再生障碍性贫血:EBMT-SAAWP RACE研究3期随机优越性研究的长期结果

2026-07-280
OAAI
Corticosteroid resistance is predetermined by early immune response dynamics at acute graft-versus-host disease onset

糖皮质激素抵抗是由急性移植物抗宿主病发作早期的免疫反应动力学预先决定的。

2026-04-080
PRE
Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report

造血干细胞移植对于实现再生障碍性贫血后髓系肿瘤的长期生存有效:欧洲血液和骨髓移植学会严重再生障碍性贫血报告

2026-01-010
OA
Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability

低风险MDS患者的移植治疗:一项基于供者可及性的前瞻性II期试验

2025-10-100
OAAI
Recursive Partitioning to Differentiate Acquired From Inherited Bone Marrow Failure Syndromes

递归划分以区分获得性与遗传性骨髓衰竭综合征

2025-09-160
OAAI
Allogeneic hematopoietic stem cell transplantation in germline DDX41 mutated patients with myeloid malignancies

同种异基因造血干细胞移植在种系DDX41突变伴髓系恶性肿瘤患者中的应用

2025-09-110
OAAI
Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan

在阵发性夜间血红蛋白尿症患者中,接受Pegcetacoplan治疗的患者疗效和安全性可维持长达3年。

2025-07-280
OA
Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan

帕妥木单抗(Iptacopan)三项III期临床试验中阵发性夜间血红蛋白尿(PNH)患者的症状和影响报告的有意义变化。

2025-07-220
PRE
Strategies for early detection and detailed characterization of oral lesions and head and neck squamous cell carcinoma in Fanconi anemia patients

范可尼贫血患者口腔病变和头颈部鳞状细胞癌的早期检测与详细表征策略

2025-05-010
PRE
The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT

ABO配型对异基因造血细胞移植结局的影响:欧洲血液和骨髓移植协会移植并发症工作组的一项当代综合性研究

2025-04-170
PRE
Antihuman T Lymphocyte Globulin Fresenius in Graft-Versus-Host Disease Prophylaxis for Unrelated Hematopoietic Stem Cell Transplantation After Myeloablative Conditioning: A Long-Term Real-Life Retrospective Study

抗人T淋巴细胞球蛋白Fresenius预防清髓预处理后无关造血干细胞移植的移植物抗宿主病: 一项长期的现实生活回顾性研究

2024-12-040
PRE
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMT
2024-11-280
PRE
Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities

脑血管病变结局及认知表现:比较异基因干细胞移植与标准护理在伴有异常脑血流速度的儿童镰状细胞贫血患者中入组Drepagreffe试验10年后的结果

BLOOD
IF23.1
2024-11-250
PRE